Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): A randomised controlled phase 2 trial

The Lancet Oncology

Volumn 15, Issue 9, 2014, Pages 943-953

  Taal, Walter ^a   Oosterkamp, Hendrika M ^b   Walenkamp, Annemiek M E ^c   Dubbink, Hendrikus J ^a   Beerepoot, Laurens V ^d   Hanse, Monique C J ^e   Buter, Jan ^f   Honkoop, Aafke H ^g   Boerman, Dolf ^h   de Vos, Filip Y F ⁱ   Dinjens, Winand N M ^a   Enting, Roelien H ^c   Taphoorn, Martin J B ^b   van den Berkmortel, Franchette W P J ^h   Jansen, Rob L H ^j   Brandsma, Dieta ^k   Bromberg, Jacoline E C ^a   van Heuvel, Irene ^a   Vernhout, René M ^a   van der Holt, Bronno ^a   Van Den Bent, Martin J ^a   more..

^a ERASMUS MC CANCER INSTITUTE   (Netherlands)

^b MEDICAL CENTER HAAGLANDEN   (Netherlands)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^d CPRLab   (Netherlands)

^e CATHARINA HOSPITAL   (Netherlands)

^f VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^g ISALA HOSPITAL   (Netherlands)

^h Department of Oncology VU University Medical Center ^*  (Netherlands)

ⁱ UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^j MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^k ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; LOMUSTINE; TEMOZOLOMIDE; DRUG COMBINATION; MONOCLONAL ANTIBODY;

ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CHEMORADIOTHERAPY; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; GLIOBLASTOMA; HUMAN; HYPERTENSION; INFECTION; INTENTION TO TREAT ANALYSIS; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; OPEN STUDY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; THROMBOCYTE COUNT; THROMBOCYTOPENIA; THROMBOSIS; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; ADOLESCENT; BRAIN NEOPLASMS; CANCER STAGING; CLINICAL TRIAL; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG COMBINATION; FOLLOW UP; INTRAVENOUS DRUG ADMINISTRATION; MAXIMUM TOLERATED DOSE; MIDDLE AGED; MORTALITY; NEOPLASM RECURRENCE, LOCAL; ORAL DRUG ADMINISTRATION; PATHOLOGY; SURVIVAL; TUMOR INVASION; YOUNG ADULT;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; BRAIN NEOPLASMS; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; GLIOBLASTOMA; HUMANS; INFUSIONS, INTRAVENOUS; LOMUSTINE; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; SURVIVAL ANALYSIS; YOUNG ADULT;

EID: 84904913239     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(14)70314-6     Document Type: Article

References (38)

1. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005, 352:987-996.
2. Stupp R, Hegi ME, Mason WP, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009, 10:459-466.
3. Wick W, Puduvalli VK, Chamberlain MC, et al. Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma. J Clin Oncol 2010, 28:1168-1174.
4. Batchelor TT, Mulholland P, Neyns B, et al. Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma. J Clin Oncol 2013, 31:3212-3218.
5. Stark-Vance V Bevacizumab and CPT-11 in the treatment of relapsed malignant glioma. Neuro-oncol 2005, 7:369. (abstr 342).
6. Vredenburgh JJ, Desjardins A, Herndon JE, et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 2007, 25:4722-4729.
7. Kreisl TN, Kim L, Moore K, et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 2009, 27:740-745.
8. Friedman HS, Prados MD, Wen PY, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 2009, 27:4733-4740.
9. Gilbert MR, Dignam JJ, Armstrong TS, et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med 2014, 370:699-708.
10. Chinot OL, Wick W, Mason W, et al. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med 2014, 370:709-722.
11. Norden AD, Young GS, Setayesh K, et al. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology 2008, 70:779-787.
12. Zuniga RM, Torcuator R, Jain R, et al. Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan. J Neurooncol 2009, 91:329-336.
13. Batchelor TT, Sorensen AG, di Tomaso E, et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 2007, 11:83-95.
14. Wick A, Dorner N, Schafer N, Hofer S, et al. Bevacizumab does not increase the risk of remote relapse in malignant glioma. Ann Neurol 2011, 69:586-592.
15. Pope WB, Xia Q, Paton VE, et al. Patterns of progression in patients with recurrent glioblastoma treated with bevacizumab. Neurology 2011, 76:432. 427.
16. Chamberlain MC Radiographic patterns of relapse in glioblastoma. J Neurooncol 2011, 101:319-323.
17. van den Bent MJ, Vogelbaum MA, Wen PY, Macdonald DR, Chang SM End point assessment in gliomas: novel treatments limit usefulness of classical Macdonald's Criteria. J Clin Oncol 2009, 27:2905-2908.
18. Wen PY, Macdonald DR, Reardon DA, et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 2010, 28:1963-1972.
19. Brandes AA, Franceschi E, Gorlia T, et al. Appropriate end-points for right results in the age of antiangiogenic agents: future options for phase II trials in patients with recurrent glioblastoma. Eur J Cancer 2012, 48:896-903.
20. Questions and answers on on the recommendation for the refusal of a change to the marketing authorisation for Avastin European Medicines Agency. http://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion/human/000582/WC500018390.pdf.
21. van den Bent MJ, Hartmann C, Preusser M, et al. Interlaboratory comparison of IDH mutation detection. J Neurooncol 2013, 112:173-178.
22. Esteller M, Toyota M, Sanchez-Cespedes M, et al. Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is associated with G to A mutations in K-ras in colorectal tumorigenesis. Cancer Res 2000, 60:2368-2371.
23. A'Hern RP Sample size tables for exact single-stage phase II designs. Stat Med 2001, 20:859-866.
24. Gorlia T, Stupp R, Brandes AA, et al. New prognostic factors and calculators for outcome prediction in patients with recurrent glioblastoma: a pooled analysis of EORTC Brain Tumour Group phase I and II clinical trials. Eur J Cancer 2012, 48:1176-1184.
25. Vredenburgh JJ, Desjardins A, Herndon JE, et al. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res 2007, 13:1253-1259.
26. Grossman SA, Ye X, Piantadosi S, et al. Survival of patients with newly diagnosed glioblastoma treated with radiation and temozolomide in research studies in the United States. Clin Cancer Res 2010, 16:2443-2449.
27. Boxerman JL, Zhang Z, Safriel Y, et al. Early post-bevacizumab progression on contrast-enhanced MRI as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 Central Reader Study. Neuro Oncol 2013, 15:945-954.
28. Gállego Pérez-Larraya J, Lahutte M, Petrirena G, et al. Response assessment in recurrent glioblastoma treated with irinotecan-bevacizumab: comparative analysis of the Macdonald, RECIST, RANO, and RECIST + F criteria. Neuro Oncol 2012, 14:667-673.
29. Prados M, Cloughesy T, Samant M, et al. Response as a predictor of survival in patients with recurrent glioblastoma treated with bevacizumab. Neuro Oncol 2011, 13:143-151.
30. Wefel JS, Cloughesy T, Zazzali JL, et al. Neurocognitive function in patients with recurrent glioblastoma treated with bevacizumab. Neuro Oncol 2011, 13:660-668.
31. Dickson PV, Hamner JB, Sims TL, et al. Bevacizumab-induced transient remodeling of the vasculature in neuroblastoma xenografts results in improved delivery and efficacy of systemically administered chemotherapy. Clin Cancer Res 2007, 13:3942-3950.
32. Cesca M, Bizzaro F, Zucchetti M, Giavazzi R Tumor delivery of chemotherapy combined with inhibitors of angiogenesis and vascular targeting agents. Front Oncol 2013, 3:259.
33. Parsons DW, Jones S, Zhang X, et al. An integrated genomic analysis of human glioblastoma multiforme. Science 2008, 321:1807-1812.
34. Lv S, Teugels E, Sadones J, et al. Correlation between IDH1 gene mutation status and survival of patients treated for recurrent glioma. Anticancer Res 2011, 31:4457-4463.
35. Noushmehr H, Weisenberger DJ, Diefes K, et al. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell 2010, 17:510-522.
36. Hegi ME, Diserens A-C, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005, 352:997-1003.
37. Wick W, Platten M, Meisner C, et al. Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. Lancet Oncol 2012, 13:707-715.
38. Malmstrom A, Gronberg BH, Marosi C, et al. Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. Lancet Oncol 2012, 13:916-926.